MA38679A1 - Modulateurs du récepteur de cxcr7 - Google Patents

Modulateurs du récepteur de cxcr7

Info

Publication number
MA38679A1
MA38679A1 MA38679A MA38679A MA38679A1 MA 38679 A1 MA38679 A1 MA 38679A1 MA 38679 A MA38679 A MA 38679A MA 38679 A MA38679 A MA 38679A MA 38679 A1 MA38679 A1 MA 38679A1
Authority
MA
Morocco
Prior art keywords
cxcr7
modulators
receiver modulators
formula
receiver
Prior art date
Application number
MA38679A
Other languages
English (en)
Other versions
MA38679B1 (fr
Inventor
Thierry Kimmerlin
Heinz Fretz
Philippe Guerry
Francois Lehembre
Julien Pothier
Hervé Siendt
Anja Valdenaire
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA38679A1 publication Critical patent/MA38679A1/fr
Publication of MA38679B1 publication Critical patent/MA38679B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

L'invention concerne des dérivés de formule (i), dans laquelle (r1)n, r 2a, r 2b, r 3a, r 3b, r 4, l1, l2, x, y et ar1 sont tels que définis dans la description, ainsi que leur préparation, des sels pharmaceutiquement acceptables de ceux-ci et leur utilisation en tant que produits pharmaceutiques, des compositions pharmaceutiques contenant au moins un composé de formule (i), et en particulier leur utilisation en tant que modulateurs du récepteur de cxcr7
MA38679A 2013-05-30 2014-05-28 Modulateurs du récepteur de cxcr7 MA38679B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013054478 2013-05-30
PCT/IB2014/061774 WO2014191929A1 (fr) 2013-05-30 2014-05-28 Modulateurs du récepteur de cxcr7

Publications (2)

Publication Number Publication Date
MA38679A1 true MA38679A1 (fr) 2018-07-31
MA38679B1 MA38679B1 (fr) 2019-12-31

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38679A MA38679B1 (fr) 2013-05-30 2014-05-28 Modulateurs du récepteur de cxcr7

Country Status (31)

Country Link
US (1) US9920010B2 (fr)
EP (1) EP3004082B1 (fr)
JP (1) JP6393749B2 (fr)
KR (1) KR102302580B1 (fr)
CN (1) CN105263924B (fr)
AR (1) AR096490A1 (fr)
AU (1) AU2014272718B2 (fr)
BR (1) BR112015030095B1 (fr)
CA (1) CA2912133C (fr)
CL (1) CL2015003470A1 (fr)
CY (1) CY1119537T1 (fr)
DK (1) DK3004082T3 (fr)
EA (1) EA028604B1 (fr)
ES (1) ES2645470T3 (fr)
HK (1) HK1223353A1 (fr)
HR (1) HRP20171597T1 (fr)
HU (1) HUE036649T2 (fr)
IL (1) IL242782B (fr)
LT (1) LT3004082T (fr)
MA (1) MA38679B1 (fr)
MX (1) MX364104B (fr)
MY (1) MY173564A (fr)
NO (1) NO3004082T3 (fr)
PH (1) PH12015502632B1 (fr)
PL (1) PL3004082T3 (fr)
PT (1) PT3004082T (fr)
SG (1) SG11201509057UA (fr)
SI (1) SI3004082T1 (fr)
TW (1) TWI640510B (fr)
UA (1) UA118562C2 (fr)
WO (1) WO2014191929A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
CN107001279B (zh) 2014-12-01 2020-10-20 爱杜西亚药品有限公司 Cxcr7受体调节剂
US20170112831A1 (en) * 2015-10-23 2017-04-27 James MERRITT Use of ccr1 antagonists as a treatment for tumors of the central nervous system
WO2018019929A1 (fr) 2016-07-28 2018-02-01 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur de cxcr7 pipéridine
HRP20211533T1 (hr) 2017-05-18 2022-01-07 Idorsia Pharmaceuticals Ltd Derivati fenila kao modulatori receptora pge2
EP3625228B1 (fr) 2017-05-18 2021-07-07 Idorsia Pharmaceuticals Ltd Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
EA202091746A1 (ru) 2018-01-26 2020-11-26 Идорсия Фармасьютиклз Лтд Кристаллические формы (1-пиримидин-2-ил-циклопропил)амида (3s,4s)-1-циклопропилметил-4-{[5-(2,4-дифторфенил)изоксазол-3-карбонил]амино}пиперидин-3-карбоновой кислоты

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
ZA991301B (en) 1998-02-18 1999-09-13 Neurosearch As Glutamate receptor modulators.
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
EP1341765A1 (fr) 2000-12-07 2003-09-10 AstraZeneca AB Composes therapeutiques
KR101061352B1 (ko) * 2002-12-20 2011-08-31 케모센트릭스 인간 종양-발현된 ｃｃｘｃｋｒ2의 저해물질
ES2353549T3 (es) * 2005-11-10 2011-03-03 Chemocentryx, Inc. Quinolonas sustituidas y métodos de uso.
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
CN107001279B (zh) 2014-12-01 2020-10-20 爱杜西亚药品有限公司 Cxcr7受体调节剂

Also Published As

Publication number Publication date
IL242782B (en) 2019-06-30
WO2014191929A1 (fr) 2014-12-04
US9920010B2 (en) 2018-03-20
PT3004082T (pt) 2017-11-13
TW201529557A (zh) 2015-08-01
CN105263924A (zh) 2016-01-20
MX2015016429A (es) 2016-03-01
HUE036649T2 (hu) 2018-07-30
EP3004082A1 (fr) 2016-04-13
AR096490A1 (es) 2016-01-13
TWI640510B (zh) 2018-11-11
JP2016520120A (ja) 2016-07-11
PH12015502632A1 (en) 2016-03-07
UA118562C2 (uk) 2019-02-11
CY1119537T1 (el) 2018-03-07
JP6393749B2 (ja) 2018-09-19
DK3004082T3 (en) 2017-10-02
CA2912133A1 (fr) 2014-12-04
IL242782A0 (en) 2016-02-01
EP3004082B1 (fr) 2017-08-02
EA028604B1 (ru) 2017-12-29
ES2645470T3 (es) 2017-12-05
AU2014272718B2 (en) 2018-06-28
KR20160013197A (ko) 2016-02-03
PL3004082T3 (pl) 2018-01-31
HK1223353A1 (zh) 2017-07-28
NO3004082T3 (fr) 2017-12-30
KR102302580B1 (ko) 2021-09-15
MA38679B1 (fr) 2019-12-31
BR112015030095B1 (pt) 2023-02-28
BR112015030095A2 (pt) 2022-07-12
HRP20171597T1 (hr) 2017-12-01
MY173564A (en) 2020-02-04
CA2912133C (fr) 2021-06-22
SI3004082T1 (sl) 2017-11-30
MX364104B (es) 2019-04-12
PH12015502632B1 (en) 2016-03-07
LT3004082T (lt) 2017-10-25
CN105263924B (zh) 2018-10-19
CL2015003470A1 (es) 2016-06-17
SG11201509057UA (en) 2015-12-30
NZ715530A (en) 2020-12-18
EA201501163A1 (ru) 2016-06-30
AU2014272718A1 (en) 2016-01-21
US20160107997A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA43251B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA49127B1 (fr) Dérivés d'indole n-substitués
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
UA103329C2 (ru) Соли соединений-ингибиторов вич
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
DE602006016430D1 (de) Phosphodiesteraseinhibitoren auf azolbasis